INTRODUCTION: This review investigates the role of p16(INK4a) as a marker of transcriptionally active human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) and the regional prevalence of HPV in ESCC. METHODS: PubMed, EMBASE, and the Cochrane Library were systematically searched with the purpose of identifying all studies published between January 1980 and July 2013 reporting both HPV and p16 results in a minimum of five human ESCC specimens. RESULTS: Twelve studies were identified, providing data on a total of 1383 ESCC specimens collected between 1987 and 2009 from 10 different countries. HPV DNA was detected in 12.0% (n = 161) of 1347 specimens, and p16(INK4a) was detected in 33.9% (n = 209) of 617 specimens. The HPV presence varied from 0% to 70% among the studies. The prevalence of p16(INK4a) overexpression in HPV-positive and HPV-negative specimens demonstrated no statistically significant difference, neither for the combined data (p = 0.7507) nor for any individual study, and detection of p16(INK4a) overexpression did not affect the odds of tumors being HPV positive (odds ratio = 1.0666 with 95% confidence interval 0.7040-1.6157). In a pooled analysis, the sensitivity of p16(INK4a) overexpression as a marker of HPV DNA presence was 0.35, the specificity 0.67, and the positive predictive value 0.25. CONCLUSIONS: This systematic review reports great regional variation in the prevalence of HPV in ESCC and suggests that p16(INK4a) is not a reliable marker of HPV status in ESCC.
INTRODUCTION: This review investigates the role of p16(INK4a) as a marker of transcriptionally active human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) and the regional prevalence of HPV in ESCC. METHODS: PubMed, EMBASE, and the Cochrane Library were systematically searched with the purpose of identifying all studies published between January 1980 and July 2013 reporting both HPV and p16 results in a minimum of five human ESCC specimens. RESULTS: Twelve studies were identified, providing data on a total of 1383 ESCC specimens collected between 1987 and 2009 from 10 different countries. HPV DNA was detected in 12.0% (n = 161) of 1347 specimens, and p16(INK4a) was detected in 33.9% (n = 209) of 617 specimens. The HPV presence varied from 0% to 70% among the studies. The prevalence of p16(INK4a) overexpression in HPV-positive and HPV-negative specimens demonstrated no statistically significant difference, neither for the combined data (p = 0.7507) nor for any individual study, and detection of p16(INK4a) overexpression did not affect the odds of tumors being HPV positive (odds ratio = 1.0666 with 95% confidence interval 0.7040-1.6157). In a pooled analysis, the sensitivity of p16(INK4a) overexpression as a marker of HPV DNA presence was 0.35, the specificity 0.67, and the positive predictive value 0.25. CONCLUSIONS: This systematic review reports great regional variation in the prevalence of HPV in ESCC and suggests that p16(INK4a) is not a reliable marker of HPV status in ESCC.
Authors: Kai Wang; Adrienne Johnson; Siraj M Ali; Samuel J Klempner; Tanios Bekaii-Saab; Jeffrey L Vacirca; Depinder Khaira; Roman Yelensky; Juliann Chmielecki; Julia A Elvin; Doron Lipson; Vincent A Miller; Philip J Stephens; Jeffrey S Ross Journal: Oncologist Date: 2015-09-02
Authors: Gordana Halec; Markus Schmitt; Sam Egger; Christian C Abnet; Chantal Babb; Sanford M Dawsey; Christa Flechtenmacher; Tarik Gheit; Martin Hale; Dana Holzinger; Reza Malekzadeh; Philip R Taylor; Massimo Tommasino; Margaret I Urban; Tim Waterboer; Michael Pawlita; Freddy Sitas Journal: Int J Cancer Date: 2016-01-21 Impact factor: 7.396
Authors: Lauren J Beesley; Peter G Hawkins; Lahin M Amlani; Emily L Bellile; Keith A Casper; Steven B Chinn; Avraham Eisbruch; Michelle L Mierzwa; Matthew E Spector; Gregory T Wolf; Andrew G Shuman; Jeremy M G Taylor Journal: Cancer Date: 2018-10-06 Impact factor: 6.860
Authors: Uma M Sachdeva; Masataka Shimonosono; Samuel Flashner; Ricardo Cruz-Acuña; Joel T Gabre; Hiroshi Nakagawa Journal: Cancer Lett Date: 2021-04-07 Impact factor: 9.756